SEARCH

SEARCH BY CITATION

References

  • 1
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 84751.
  • 2
    Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 88391.
  • 3
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 174351.
  • 4
    Hadziyannis S, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology 2006; 44: 231A.
  • 5
    Lai CL, Gane E, Hsu CW, et al. Two-year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006; 44: 222A.
  • 6
    Di Bisceglie A, Lai CL, Gane E, et al. Telbivudine Globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44: 230A.
  • 7
    Zeuzem S, Buti M, Gane EJ, et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (The Globe Study). Hepatology 2007; 46: 681A.
  • 8
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 101120.
  • 9
    Shouval D, Akarca US, Hatzis G, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J Hepatol 2006; 44: S21.
  • 10
    Colonno RJ, Rose RE, Pokornowski K. Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. J Hepatol 2007; 46: S294.
  • 11
    Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102). J Hepatol 2008; 48: S26: #57.
  • 12
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 1219.
  • 13
    Lampertico P, Viganò M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 14149.
  • 14
    Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 30713.
  • 15
    Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. J Hepatol 2007; 46: S191.
  • 16
    Lampertico P, Viganò M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007; 133: 144551.
  • 17
    Iavarone M, Lampertico P, Vigano M. Six years of on demand LAM±ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis. J Hepatol 2007; 46: S189.